Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, May 21, 2019 · 485,853,816 Articles · 3+ Million Readers

Global Personalized Medicine Market to 2024: Personalized Cancer Therapy Gets a Boost from Patient-Derived Tumor Organoids

/EIN News/ -- Dublin, Oct. 15, 2018 (GLOBE NEWSWIRE) -- The "Global Personalized Medicine Market - Types, Technologies and Applications" report has been added to ResearchAndMarkets.com's offering.

Global Personalized Medicine market is expected to witness a robust CAGR of over 11% during the 2017-2024 analysis period and projected to touch US$194.4 billion by 2024 from an estimated US$92.4 billion in 2017. By application, Oncology is estimated the largest market accounting for about 30% throughout the analysis period.

Personalized medicine has a huge potential in leading the healthcare industry with drastic changes with a key focus on diseases understanding & management integrated with advanced analytics, patient data, customized medicines and other possibilities. Personalized Medicine will transform the entire pharmaceutical value chain, from early development to companies' go-to-market models, and the next five years will be a crucial window for pharmaceutical companies to capitalize on this promise.

Companies simply cannot sit on the sidelines during this period. Instead, they need to take risks and more actively engage with stakeholders throughout the healthcare ecosystem. However, there seems to be some challenges such as an unclear regulatory framework, insufficient access to high-quality data, data privacy issues and lack of standards.

Key Topics Covered:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION
1.1 Product Outline
1.1.1 The Human Genome: What is It?
1.1.2 Personalized Medicine Defined
1.1.3 Personalized Medicine's Influence on Large Scale Studies
1.1.4 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine
1.1.5 Ramifications of Personalized Medicine for Healthcare Systems
1.1.5.1 Pharmaceutical Industry
1.1.5.2 Diagnostics Industry
1.1.5.3 Insurers
1.1.5.4 Physicians
1.1.5.5 Government Agencies
1.1.5.6 Patients
1.1.6 Personalized Medicine Product Types
1.1.6.1 Personalized Medicine Diagnostics
1.1.6.1.1 Genetic Testing
1.1.6.1.2 Direct-to-consumer Diagnostics
1.1.6.2 Personalized Medicine Therapeutics
1.1.6.2.1 Personalized Medicine Will Transform the Pharmaceutical and Healthcare Industries
1.1.6.2.2 Personalized Medical Devices
1.1.6.2.3 Genomic Medicine
1.1.6.3 Personalized Medical Care
1.1.6.3.1 Telemedicine
1.1.6.3.2 Health Information Technology
1.1.6.3.3 Diseases Management
1.1.6.4 Personalized Nutrition & Wellness
1.1.6.4.1 Complementary and Alternative Medicine
1.1.7 Personalized Medicine Technologies
1.1.7.1 Pharmacogenomics
1.1.7.1.1 Drug Metabolism
1.1.7.1.2 Applications
1.1.7.2 Point-of-Care Testing
1.1.7.2.1 Tests that are Most Apt for Specific Scenarios
1.1.7.2.2 Advantages
1.1.7.3 Stem Cell Therapy
1.1.7.3.1 Treatment with Stem Cells
1.1.7.3.2 Current Therapies
1.1.7.3.3 Future Treatments
1.1.7.4 Pharmacoproteomics
1.1.7.5 Pharmacogenetics
1.1.7.5.1 Prediction of Drug-Drug Interactions
1.1.7.5.2 Integration of Pharmacogenetics with the Healthcare System
1.1.7.5.3 Pharmacogenetic Tests
1.1.7.6 Other Personalized Medicine Technologies
1.1.7.6.1 Biochips
1.1.7.6.1.1 Fabrication of Microarrays
1.1.7.6.1.2 Protein Biochip Array and Other Microarray Technologies
1.1.7.6.1.3 Biochips Applications: Ranging from Diagnostics to Personalized Medicine
1.1.7.6.2 Metabolomics
1.1.7.6.2.1 Analytical Technologies
1.1.7.6.2.1.1 Separation Methods
Gas Chromatography (GC)
High Performance Liquid Chromatography (HPLC)
Capillary Electrophoresis (CE)
1.1.7.6.2.1.2 Detection Methods
Mass Spectrometry (MS)
Nuclear Magnetic Resonance (NMR) Spectroscopy
1.1.7.6.2.2 Major Application Areas
1.1.7.6.3 Molecular Diagnostics
1.1.7.6.3.1 Molecular Diagnostics for Personalized Medicine
1.1.7.6.4 Pharmacodynamics
1.1.7.6.5 Pharmacokinetics
1.1.7.6.6 SNP Genotyping
1.1.7.6.6.1 Core Labs
1.1.7.6.6.2 Hybridization-Based Methods
1.1.7.6.6.3 Enzyme-Based Methods
1.1.7.6.6.4 Other Post-Amplification Methods Based on Physical Properties of DNA
1.1.8 Personalized Medicine Applications
1.1.8.1 Oncology
1.1.8.1.1 Personalized Medicine in Cancer Treatment
1.1.8.1.1.1 The Promise of Personalized Medicine
1.1.8.1.1.2 Personalized Medicine as a Treatment Approach
1.1.8.1.1.3 Personalized Medicine Does Not Yet Apply to Everyone
1.1.8.1.1.4 Personalized Medicine Research Moving Forward
1.1.8.1.2 Examples of personalized medicine
1.1.8.2 Central Nervous System (CNS)
1.1.8.2.1 Personalized Medicine in Brain Metastases: A Plea for More Translational Studies
1.1.8.3 Immunology
1.1.8.3.1 Clinical Immunology
1.1.8.4 Respiratory
1.1.8.4.1 Respiratory System: Facts, Function and Diseases
1.1.8.4.2 Diseases of the respiratory system
1.1.8.5 Other Applications Of Personalized Medicine
1.1.8.5.1 Psychiatry
1.1.8.5.2 Antiviral Therapy
1.1.8.5.3 Diabetes
1.1.8.5.4 Coagulation and blood transfusion safety

2. KEY MARKET TREDNS
2.1 Precision Medicine Enhanced through Artificial Intelligence and Blockchain Artificial Intelligence for Genome Sequencing
2.2 Personalized Cancer Therapy Gets a Boost from Patient-Derived Tumor Organoids
2.3 Patient-Derived Organoid Models of Bladder Cancer Help in Determining Tumor Evolution and Drug Response
2.4 Personalized Immunotherapy in Cancer Improved through Tumor Organoids
2.5 Future of Personalized Medicine Linked to Micorbiomics
2.6 Regenerated T Cells Can Possibly Used in Personalized Medicine

3. KEY GLOBAL PLAYERS

  • Abbott Laboratories, Inc. (United States)
  • Abbott Molecular, Inc. (United States)
  • Agilent Technologies, Inc. (United States)
  • Dako A/S (Denmark)
  • Amgen, Inc. (United States)
  • Decode Genetics (Iceland)
  • Astrazeneca Plc (United Kingdom)
  • Astellas Pharma, Inc. (Japan)
  • Bayer AG (Germany)
  • Bayer Healthcare Pharmaceuticals, Llc (Germany)
  • Celgene Corporation (United States)
  • Glaxosmithkline Plc (United Kingdom)
  • Illumina, Inc. (United States)
  • Johnson & Johnson (United States)
  • Laboratory Corporation of America (United States)
  • Merck KGaA (Germany)
  • Sigma-Aldrich Corporation (United States)
  • Novartis AG (Switzerland)
  • Roche Holding AG (Switzerland)
  • Roche Diagnostics Corporation (United States)
  • Siemens AG (Germany)
  • Siemens Healthcare GmbH (Germany)
  • Siemens Healthcare Diagnostics, Inc. (United States)
  • Takeda Pharmaceutical Company Limited (Japan)

4. KEY BUSINESS AND PRODUCT TRENDS

  • Bayer AG and Haplogen GmbH Enter into Agreement
  • Almac Discovery Ltd, Elasmogen Ltd and Innovate UK Form an Alliance on VNAR Based Oncology Platform
  • Haplogen GmbH and Bayer AG Join Hands for Drug Discovery and Development
  • Amgen, Inc and Cedars-Sinai Medical Center Collaborate on Research Programs in Personalized Medicine
  • LEO Pharma A/S to Acquire Bayer's Dermatology Unit
  • Biocartis Group NV Introduces Innovative Idylla MSI Assay
  • GlaxoSmithKline Plc and 23andMe Collaborate on Drug Development Using Human Genetics
  • MD Anderson Cancer Center and Bayer AG Collaborate on Cancer Treatment Medicine
  • FDA Approval for Beckman Coulter's Troponin (hsTnI) Assays
  • Roche and Foundation Medicine, Inc Enter into Agreement
  • LabCorp and Unilabs Join Hands on Personalized Medicine Offering
  • Abbott Develops Deep Brain Stimulation System, Life-Changing Treatment
  • Biocartis Group NV Demonstrate Idylla EGFR Mutation Test
  • Myriad Genetics Inc to Acquire Counsyl, Inc
  • Owlstone Medical Ltd Enters into Collaboration with AstraZeneca Plc
  • Boehringer Ingelheim GMBH and OSE Immunotherapeutics SA Enter into Partnership
  • PerkinElmer, Inc and Helix Enter into Agreement on Exome-based Personal Genomics
  • Daiichi Sankyo Co., Ltd and DarwinHealth Collaboration on Novel Cancer Drug Development
  • Roche, Foundation Medicine Inc, and DIAN Diagnostics Collaborate to Progress Personalized Cancer Care in China
  • Loxo Oncology and Illumina, Inc Collaborate on Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
  • Vineti and Deloitte Work on Personalized Medicine Development
  • Thermo Fisher Scientific, Inc Acquires IntegenX, Inc
  • Siemens Healthineers Launches 1.5T MRI Scanner Magnetom Sola
  • Abbott Laboratories Inc and SurModics, Inc Enter into Agreement on Next-Generation Drug-Coated Balloon
  • Almac Diagnostics and DNAnexus Join Forces
  • Roche Acquires Flatiron Health, Inc.
  • Myriad Genetics, Inc Enters an Agreement with AstraZeneca Plc
  • BIOCRATES Life Sciences AG Acquires Metanomics Health GmbH
  • Roche and GE Healthcare Enter into Partnership on Individualized Oncology and Critical Care Treatment
  • Illumina, Inc and KingMed Diagnostics Agree on Next-Generation Sequencing (NGS) Technology
  • Bayer AG Receives Chinese Food and Drug Administration (CFDA) Approval for Stivarga (Regorafenib) Tablets for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)
  • Fortuna Fix Inc Raises Funds for Stem Cell Treatments for Parkinson's Disease and Spinal Cord Injuries
  • Bayer AG and Loxo Oncology Inc to Develop and Commercialize Two Novel Oncology Therapies
  • Biocartis Group NV Unveils Two New CE-marked IVD Liquid Biopsy Tests
  • Boehringer Ingelheim GmbH and Dicerna Pharmaceuticals, Inc Agree on Nonalcoholic Steatohepatitis (NASH) Treatment Development
  • Laboratory Corporation of America Holdings Launch PD-L1 IHC 28-8 PharmDx Assay
  • Laboratory Corporation of America Holdings Company Enters into Partnership with MedReleaf Corp
  • Siemens Healthineers Develops Nexaris Therapy Suite
  • Abbott Laboratories, Inc Receives FDA 510(k) Clearance for Alinity CI-Series Instruments
  • The National Institutes of Health (NIH) and Bio-Pharmaceutical Companies Collaborate on Personalized Medicine Approach to Cancer Care
  • Myriad Genetics, Inc Offers Personalized Medicine Tests for Breast Cancer
  • Abbott Laboratories Inc, Acquires Alere, Inc
  • Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) Develops Cancer Immunotherapies and Advance Personalized Medicine
  • Bristol-Myers Squibb and Daiichi Sankyo Co., Ltd Enter into Clinical Collaboration in HER2-Expressing Breast and Bladder Cancers
  • AstraZeneca plc and Takeda Pharmaceutical Company Limited today announce Partnership
  • Amgen's Therapy Vectibix (panitumumab) Receives FDA Approval
  • Blue Shield of California Develops Agendia's MammaPrint Technology
  • Baxter International, Inc and Dorizoe Lifesciences Limited Enter into Agreement
  • Thermo Fisher Scientific Inc and BIOCRATES Life Sciences AG Develop AbsoluteIDQ p400 HR kit
  • Agilent Technologies Inc, Expands the Usage of Dako PD-L1 IHC 28-8 PharmDx Test in Europe
  • Abbott Laboratories Inc Unveils Nutrition Drinks
  • Myriad Genetics Inc and BeiGene, Ltd Collaborate on Companion Diagnostics Development for Personalized Medicine Drive
  • Illumina, Inc Reveals Somatic Genetic Alterations to Clinical Interpretation of Variants in Cancer (CIViC)
  • Almac Diagnostics and EORTC Join Forces on Tumor Molecular Profiling
  • Bristol-Myers Squibb and GRAIL, Inc Enter into Personalized Medicine Collaboration
  • GRAIL, Inc Invests Heavily in New Early Detection Techniques for Cancer
  • Novartis Pharmaceuticals Corporation and Cota Inc Agree to Develop Breast Cancer Treatment
  • Baxter International, Inc and ScinoPharm Taiwan, Ltd Enter into Strategic Partnership
  • Agilent Technologies Inc to Acquire Multiplicom N.V
  • Abbott Introduces New Ensite Precision Cardiac Mapping System
  • Royal Philips and Illumina Inc Collaborate on Combined Genomics Solutions for Oncology
  • Bayer AG and Leica Biosystems Develop Companion Diagnostic Test for Cancer Patients
  • Genomic Health, Inc reveals Results from Multiple Oncotype DX Studies
  • Baxter International, Inc Acquires Claris Injectables Limited
  • NantHealth Inc and Oncotest-Teva Enter into Agreement
  • Asuragen Inc., Introduces QuantideX NGS RNA Lung Cancer Kit
  • Thermo Fisher Scientific, Inc Enters into Distribution Agreement with Biocartis Group NV
  • Johns Hopkins University and Bristol-Myers Squibb Collaborate on Immune Checkpoint-Based Cancer Therapy
  • Danaher Corporation Acquires Cepheid, Inc
  • Assurex Health, Inc. Presents GeneSight Personalized Medicine Test for Anxiety Disorder
  • IBM Watson Health and Quest Diagnostics Inc Introduce Watson-Powered Genomic Sequencing Service
  • Genomic Health, Inc Presents Personalized Medicine Studies at ESMO 2016 Congress
  • Genentech, Inc and BioNtech Agree on Personalized Cancer Vaccine Development
  • Asuragen Inc, Unveils AmplideX PCR/CE C9orf72 Kit
  • DNA Genotek's ORAcollectDx Collection Device Receives FDA 510(k) Clearance
  • deCODE Genetics Discovers Rare Variation In The Sequence Of The Human Genome
  • QIAGEN NV Unveils Targeted RNA Panels for Next-Generation Sequencing
  • National Reference Laboratory and LabCorp Develop World-Class Assays for Personalized Medicine

5. GLOBAL MARKET OVERVIEW
5.1 Global Personalized Medicine Market Overview by Product Type
5.1.1 Personalized Medicine Product Type Market Overview by Global Region
5.1.1.1 Personalized Medicine Diagnostics
5.1.1.2 Personalized Medical Care
5.1.1.3 Personalized Medicine Therapeutics
5.1.1.4 Personalized Nutrition & Wellness
5.2 Global Personalized Medicine Market Overview by Technology
5.2.1 Personalized Medicine Technology Market Overview by Global Region
5.2.1.1 Pharmacogenomics
5.2.1.2 Point-of-Care Testing
5.2.1.3 Stem Cell Therapy
5.2.1.4 Pharmacoproteomics
5.2.1.5 Pharmacogenetics
5.2.1.6 Other Technologies
5.3 Global Personalized Medicine Market Overview by Application
5.3.1 Personalized Medicine Application Market Overview by Global Region
5.3.1.1 Oncology
5.3.1.2 Central Nervous System (CNS)
5.3.1.3 Immunology
5.3.1.4 Respiratory
5.3.1.5 Other Applications

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

6. NORTH AMERICA
Major Market Players
Abbott Laboratories, Inc. (United States)
Agilent Technologies, Inc. (United States)
Amgen, Inc. (United States)
Asuragen, Inc. (United States)
Baxter International, Inc. (United States)
Beckman Coulter, Inc. (United States)
BG Medicine, Inc. (United States)
Biogen, Inc. (United States)
Bristol-Myers Squibb (United States)
Celera Corporation (United States)
Celgene Corporation (United States)
Celldex Therapeutics, Inc. (United States)
Cepheid, Inc. (United States)
DNA Genotek, Inc. (Canada)
Eli Lilly and Company (United States)
Exact Sciences Corporation (United States)
Exagen Diagnostics, Inc. (United States)
Genelex Corporation (The Unites States)
Genentech, Inc. (United States)
Genewiz, Inc. (United States)
Genomic Health, Inc. (United States)
Genzyme Corporation (United States)
Historx, Inc. (United States)
Hologic, Inc. (United States)
Illumina, Inc. (United States)
Ingenuity Systems, Inc. (United States)
Johnson & Johnson (United States)
Laboratory Corporation of America (United States)
Luminex Corporation (United States)
Millennium Health, LLC. (United States)
Mylan, N.V (United States)
Myriad Genetics, Inc. (United States)
Nanostring Technologies, Inc. (United States)
Perkinelmer, Inc. (United States)
Caliper Life Sciences, Inc. (United States)
Pfizer, Inc. (United States)
Precision Biologics, Inc. (United States)
Promega Corporation (United States)
Roche Diagnostics Corporation (United States)
Siemens Healthcare Diagnostics, Inc. (United States)
Sigma-Aldrich Corporation (United States)
ThermoFisher Scientific, Inc. (United States)
Life Technologies Corporation (United States)

7. EUROPE

Major Market Players
Agendia B.V. (The Netherlands)
Astrazeneca Plc (United Kingdom)
Bayer AG (Germany)
Bayer Healthcare Pharmaceuticals (Germany)
Biocartis NV (Belgium)
Boehringer Ingelheim GmbH (Germany)
Cytolon AG (Germany)
Dako A/S (Denmark)
Decode Genetics (Iceland)
Eagle Genomics Ltd. (United Kindom)
Evotec AG (Germany)
GE Healthcare Ltd. (United Kingdom)
GlaxoSmithKline Plc (United Kingdom)
Intomics A/S (Denmark)
Medtronic Plc (Ireland)
Merck KGAa (Germany)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Qiagen N.V. (The Netherlands)
Roche Holding AG (Switzerland)
Sanofi (France)
Siemens AG (Germany)
Siemens Healthcare GmbH (Germany)
The European Personalised Medicine Association (EPEMED) (Luxembourg)

8. ASIA-PACIFIC
Astellas Pharma, Inc. (Japan)
Daiichi Sankyo Company Limited (Japan)
Mitsubishi Tanabe Pharma Corporation (Japan)
Takeda Pharmaceutical Company Limited (Japan)

9. SOUTH AMERICA

10. REST OF WORLD

Major Market Players
Rosetta Genomics Ltd. (Israel)
TEVA Pharmaceutical Industries Ltd. (Israel)

For more information about this report visit https://www.researchandmarkets.com/research/9lfncx/global?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Genomics
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release